CRISPR 和 Cas 基因市场增长、规模、份额、趋势、关键参与者分析及 2030 年预测

  • Report Code : TIPRE00016686
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

 

[研究报告] CRISPR 和 Cas 基因市场规模预计将从 2022 年的 27.8 亿美元增长到 2030 年的 151 亿美元;预计 2022-2030 年期间市场复合年增长率为 23.6%。

 

 

市场洞察和分析师观点:

该报告包括当前 CRISPR 和 Cas 基因市场趋势及其在预测期内可预见的影响所带来的增长前景。癌症和遗传病患病率的不断上升,以及越来越多地采用基于 CRISPR 的筛选方法并改进基因组靶点等因素推动了市场的增长。然而,与 CRISPR 技术相关的脱靶效应和伦理问题阻碍了市场的增长。在未来几年,增加基因组研究的资金以及为证明 CRISPR 在基因组学中的有效性而做出的努力可能会为市场带来新的趋势。

CRISPR 技术可用于识别许多肿瘤中的突变。它们识别特定于人类肿瘤的修饰蛋白。因此,利用 CRISPR 技术实现的针对癌症等慢性疾病的个性化治疗推动了市场扩张。此外,生物技术公司对新疗法的投资、基因组研究和开发的增加以及癌症、血源性疾病负担的增加等因素正在促进 CRISPR 和 Cas 基因市场的增长。然而,CRISPR 在药物开发和治疗程序中的使用受到其偏离目标的可能性的限制,这限制了市场的发展。

 

增长动力:

 

癌症和遗传疾病患病率上升推动市场增长

根据美国癌症协会的数据,2022 年美国被诊断出患有癌症的人数估计为 190 万。此外,2022 年 11 月发表在《自然》杂志上的一篇论文指出,研究人员可以使用 CRISPR 基因编辑来改变免疫细胞,以识别特定于人体肿瘤的改变蛋白质。然后可以安全地将这些细胞运送到体内,找到要消除的目标,从而有助于针对癌症和其他慢性疾病的个性化治疗方案。

遗传疾病的日益流行进一步推动了对基因编辑技术(如 CRISPR 和 Cas 基因)的需求。根据世界卫生组织 (WHO) 的数据,全球有数百万人受到遗传疾病的影响,几乎每 20 个活产婴儿中就有 1 个患有遗传疾病。CRISPR/Cas 系统可用作开发各种遗传疾病治疗方法的潜在工具,包括镰状细胞性贫血、囊性纤维化和亨廷顿氏病。许多临床试验正在进行中,以测试基于 CRISPR 的疗法在遗传疾病中的安全性和有效性。因此,在治疗癌症和其他慢性和遗传疾病的各个治疗领域对 CRISPR 和 Cas 基因技术的需求日益增加CRISPR and Cas genes. According to the World Health Organization (WHO), millions of people worldwide are affected by genetic disorders, as almost 1 in 20 live births has a genetic disorder. The CRISPR/Cas system can be used as a potential tool in developing treatment approaches for various genetic diseases, including sickle cell anemia, cystic fibrosis, and Huntington's disease. Many clinical trials are ongoing for testing the safety and effectiveness of CRISPR-based therapies in genetic disorders. Thus, the increasing demand for CRISPR and Cas gene technologies in various therapeutic areas to treat cancer and other chronic and genetic diseases推动 CRISPR 和 Cas 基因市场的增长。CRISPR and Cas gene market growth.

 

定制此报告以满足您的需求

您可以免费定制任何报告,包括本报告的部分内容、国家级分析、Excel 数据包,以及为初创企业和大学提供优惠和折扣

CRISPR 和 Cas 基因市场: and Cas Gene Market:

CRISPR and Cas Gene Market
  • 获取此报告的关键市场趋势。
    这个免费样品将包括数据分析,从市场趋势到估计和预测。

 

报告细分和范围:

CRISPR 和 Cas 基因市场分析是通过考虑以下部分来进行的:产品和服务、应用和最终用户。

 

节段分析:

根据应用,CRISPR 和 Cas 基因市场分为生物医学和农业。生物医学领域在 2022 年占据了更大的市场份额。预计同一领域在预测期内的复合年增长率将达到 23.8%。CRISPR 基因编辑技术正在生命科学的不同领域使用。成熟的递送方法和纳米载体的使用进一步提高了该技术的有效性和特异性。已经进行了各种研究来解释使用此方法修改人类体细胞和多能干细胞基因组。一些公司还提供商业试剂盒和服务,以通过使用 CRISPR基因编辑技术协助研究人员。

通过创新育种技术提高农业产量,使全世界更容易获得营养丰富的食物。2019 年 6 月,冷泉港实验室的研究人员利用 CRISPR/Cas9 技术诱导番茄开花抑制因子突变,导致番茄快速开花,生长更紧密,最终实现早期产量。

CRISPR 和 Cas 基因市场按产品和服务分为产品和服务。产品部分在 2022 年占据了更大的市场份额。预计同一部分在预测期内的复合年增长率将达到 23.9%。为了满足日益增长的需求,已经开发并推出了 CRISPR 和 Cas 基因编辑试剂盒等众多尖端技术。这些试剂盒在整体市场中的份额激增归因于改进的单一产品的可用性,这些产品可以实现不同的目标,包括简单的基因敲除、减少脱靶切割、选择性基因组切割、基因组工程和更高的特异性。在预测期内,增加与基因编辑相关的研发投资将进一步使整个 CRISPR 和 Cas 基因市场受益。

根据最终用户,市场分为生物技术和制药公司、学术和政府研究机构以及合同研究组织 (CRO) 和 CDMO。生物技术和制药公司部门在 2022 年占据了 CRISPR 和 Cas 基因市场的最大份额。预计在预测期内,其复合年增长率最高,为 24.2%。生物技术和制药公司使用这些技术快速识别和验证新的治疗目标,并在更短的时间内创建更好的人类疾病生物模型。他们还将基因改造技术用于商业目的。

 

区域分析:

CRISPR 和 Cas 基因市场报告的范围包括北美、欧洲、亚太地区、南美和中美以及中东和非洲。2022 年,北美占据了最大的 CRISPR 和 Cas 基因市场份额。该地区的市场增长受到生物制药行业蓬勃发展的研发业务以及多家制药公司参与开发新型疗法的推动。2020 年 5 月,默克集团获得美国食品药品管理局 (FDA) 批准的两项 CRISPR Cas9 驱动的基因编辑专利。此外,美国和加拿大的各种联邦举措支持农业生物技术研究和基于 CRISPR 的植物产品的商业发布。许多制药和种子公司分别投资于合作伙伴关系、收购和合作等增长战略,以推动制药市场和作物生长,这将进一步增强这些行业对 CRISPR 技术的需求。

预计欧洲将在全球 CRISPR 和 Cas 基因市场中占据第二大份额。欧洲当局对新技术(包括基因治疗和转基因生物)出台了更严格的监管。尽管监管严格,但该地区仍在生物医学、医疗、农业和治疗应用中迅速采用 CRISPR 技术。

预计在预测期内,亚太地区的市场复合年增长率将达到 24.3%,是最快的。该地区市场的增长归因于政府加大对研发新疗法的投资。中国的公司和研究机构正在对用于药物开发的基因组编辑进行研究,他们最近宣布了几项临床试验,以寻求批准将 CRISPR 用于癌症治疗。2021 年 3 月,日本生物科技公司 Setsuro Tech 获得了由都柏林 ERS ​​Genomics 开发的 CRISPR-Cas9 技术的专利。预计这些举措将在未来推动亚太地区采用 CRISPR 技术。

 

 

CRISPR 和 Cas 基因市场区域洞察

Insight Partners 的分析师已详细解释了预测期内影响 CRISPR 和 Cas 基因市场的区域趋势和因素。本节还讨论了北美、欧洲、亚太地区、中东和非洲以及南美洲和中美洲的 CRISPR 和 Cas 基因市场细分和地理位置。

CRISPR and Cas Gene Market
  • 获取 CRISPR 和 Cas 基因市场的区域特定数据

CRISPR 和 Cas 基因市场报告范围

报告属性细节
2022 年市场规模27.8亿美元
2030 年市场规模151亿美元
全球复合年增长率(2022 - 2030 年)23.6%
史料2020-2022
预测期2022-2030
涵盖的领域按产品和服务
  • 產品與服務
按应用
  • 生物医学和农业
按最终用户
  • 生物科技及制药公司
  • 学术界和政府研究机构
  • 合同研究组织和 CDMO
覆盖地区和国家北美
  • 我们
  • 加拿大
  • 墨西哥
欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
亚太
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
南美洲和中美洲
  • 巴西
  • 阿根廷
  • 南美洲和中美洲其他地区
中东和非洲
  • 南非
  • 沙特阿拉伯
  • 阿联酋
  • 中东和非洲其他地区
市场领导者和主要公司简介
  •  
  • CRISPR 治疗
  • BRAIN 生物技术股份公司
  • 赛默飞世尔科技
  • 默克公司
  • 埃迪塔斯医药
  • 宝生物
  • 金斯瑞
  • Qigen
  • 新英格兰生物实验室

市场参与者密度:了解其对商业动态的影响

由于消费者偏好的不断变化、技术进步以及对产品优势的认识不断提高等因素,最终用户需求不断增加,推动了 CRISPR 和 Cas 基因市场快速增长。随着需求的增加,企业正在扩大其产品范围,进行创新以满足消费者需求,并利用新兴趋势,从而进一步推动市场增长。

市场参与者密度是指在特定市场或行业内运营的企业或公司的分布情况。它表明在给定市场空间中,相对于其规模或总市场价值,有多少竞争对手(市场参与者)存在。

在 CRISPR 和 Cas 基因市场运营的主要公司有:

  1. CRISPR 治疗
  2. BRAIN 生物技术股份公司
  3. 赛默飞世尔科技
  4. 默克公司
  5. 埃迪塔斯医药

免责声明上面列出的公司没有按照任何特定顺序排列。


CRISPR and Cas Gene Market

 

  • 获取 CRISPR 和 Cas 基因市场顶级关键参与者概览

 

行业发展和未来机遇:

CRISPR 和 Cas 基因市场预测可以帮助该市场的利益相关者规划其增长战略。以下列出了主要市场参与者的一些战略发展:

  • 2023 年 2 月,Ensoma 收购了 Twelve Bio ApS,以进一步开发其体内工程细胞药物组合。Twelve Bio 是一家致力于探索下一代 CRISPR-Cas 药物治疗应用的公司。
  • 2022 年 12 月,加州大学的一名研究人员开始了一项临床试验,题为“在严重镰状细胞病患者中移植成簇的规律间隔的短回文重复修饰的造血祖干细胞(CRISPR_SCD001)”,以评估使用 CRISPR/Cas9 编辑的红细胞(称为 CRISPR_SCD001 药物产品)进行造血干细胞移植(HSCT)。
  • 2022 年 11 月,麻省理工学院的研究人员开发了一种基于 CRISPR 的 PASTE 工具,可将大型 DNA 序列插入所需的细胞位置。该技术可能用于治疗各种遗传疾病。
  • 2021年11月,加拿大卫生部批准了CRISPR Therapeutics和ViaCyte提交的VCTX210临床试验申请,VCTX210是一种用于治疗1型糖尿病的CRISPR工程干细胞疗法。

 

竞争格局和重点公司:

CRISPR Therapeutics、Thermo Fisher Scientific、Merck、GenScript、Qiagen、Takara Bio Inc.、Brain Biotech AG、Intellia Therapeutics, Inc.、New England Biolabs 和 Editas Medicine, Inc. 是 CRISPR 和 Cas 基因市场报告中介绍的知名公司。这些公司专注于开发新技术、升级现有产品并扩大其地理覆盖范围,以满足全球日益增长的消费者需求。

  • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
  • PEST and SWOT Analysis
  • Market Size Value / Volume - Global, Regional, Country
  • Industry and Competitive Landscape
  • Excel Dataset
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What are the driving factors for the CRISPR and Cas gene market?

The factors driving the growth of the CRISPR and Cas gene market include the increasing prevalence of cancer and genetic diseases, and the burgeoning adoption of CRISPR-based screens with improved genomic targets.

What is CRISPR and Cas gene?

The CRISPR technology is useful in identifying mutations in many tumors. They recognize modified proteins that are specific to human tumors. The technology can safely be utilized to find their targets for elimination. Therefore, personalized treatments enabled by CRISPR technology for chronic diseases such as cancer drive the CRISPR and Cas gene market growth. In addition, factors such as investments by biotech companies in new treatments; increased genomic research and development; and the rising burden of cancer, bloodborne diseases, and so on are facilitating the expansion of the market.

What are the growth estimates for the CRISPR and Cas gene market till 2030?

The CRISPR and Cas gene market is expected to be valued at US$ 15.10 billion in 2030.

Who are the major players in the CRISPR and Cas gene market?

The CRISPR and Cas gene market majorly consists of the players such as CRISPR Therapeutics; Thermo Fisher Scientific; Merck; GenScript; Qiagen; Takara Bio Inc.; Brain Biotech AG; Intellia Therapeutics, Inc.; New England Biolabs; and Editas Medicine, Inc.

What was the estimated CRISPR and Cas gene market size in 2022?

The CRISPR and Cas gene market was valued at US$ 2.78 billion in 2022.

Which segment is dominating the CRISPR and Cas gene market?

The global CRISPR and Cas gene market, based on product & service is segmented into products and services. The products segment held a larger market share in 2022. The same segment is expected to register a higher CAGR of 23.9% during the forecast period. Based on application, the CRISPR and Cas gene market is segmented into biomedical and agriculture. The biomedical segment held a larger market share in 2022. The same segment is anticipated to register a higher CAGR of 23.8% during 2022–2030. In terms of end user, the CRISPR and Cas gene market is segmented into biotechnology and pharmaceutical companies, academics and government research institutes, and contract research organizations (CROs) and CDMOs. The biotechnology and pharmaceutical companies segment held the largest CRISPR and Cas gene market share in 2022. It is anticipated to register the highest CAGR of 24.2% during the forecast period.

Trends and growth analysis reports related to Life Sciences : READ MORE..   
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

The List of Companies - CRISPR and Cas Gene Market

  1. CRISPR Therapeutics
  2. BRAIN Biotech AG
  3. Thermo Fisher Scientific
  4. Merck KGaA
  5. Editas Medicine
  6. Takara Bio
  7. Genscript
  8. Qiagen
  9. New England Biolabs
  10. Intellia Therapeutics

Buy Now  

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.